Trxade Group Inc. (MEDS) shares are trading at higher $6.20 and the avg recommendation for the stock is Strong Buy.
To add more color to this target, the company’s high over the last year is $11.60 and the low is $4.01. Over the last 52 weeks, MEDS is down -28.24% while the S&P 500 is up 12.53%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
In the last quarter, MEDS reported a profit of $2.0 million. Trxade Group Inc. also saw revenues increase to $6.59 million. In addition, MEDS has free cash flow of -$4.01 million as of 06-2020. The company’s EBITDA came in at -$0.51 million which compares well with its peers.
MEDS booked profit margins of -6.50%, its Return on Equity (ROE) is -11.90%, and its Return on Assets is -9.60%. All told, it is clear that, MEDS needs to be on your watchlist.
Find out when MEDS reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. MEDS has a short ratio of 0.19 and outstanding shares of 7.58M.
MEDS has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 22670.0 and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -0.13. Trxade Group Inc. MEDS also noted assets of $11.73 million at the end of the last quarter. Investors should also keep an eye on sector updates as MEDS has historically followed its peers on positive news.
All told, Trxade Group Inc. MEDS has strung together solid data and demonstrated underlying fundamentals. At its current valuation, MEDS represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.
Trxade Group Inc. MEDS is now commanding a market cap of 47.68M and a float of 3.09M. MEDS is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of MEDS stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in MEDS, either long or short, and we have not been compensated for this article.